Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 2

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 2
---
 ● | a                                                                                                                                       
 sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $100,000,000   
 of our common stock that may be issued and sold under the At The Market Offering Agreement with Rodman & Renshaw LLC.                   |

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus other than the shares under the At The Market Offering Agreement will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the At The Market Offering Agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The up to $100,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $150,000,000 of securities that may be offered, issued and sold by us under the base prospectus.

The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement containing this prospectus filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION DATED FEBRUARY 14, 2025</div>

PROSPECTUS

<div align='center'>$150,000,000

TELOMIR PHARMACEUTICALS, INC.

Common Stock

Preferred Stock

Warrants

Units</div>

We may offer and sell, from time to time, in one or more offerings, together or separately, any combination of the securities described in this prospectus. The aggregate initial offering price of the securities that we offer will not exceed $150,000,000. This prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered. The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus may not be used to sell securities unless accompanied by the applicable prospectus supplement. Before investing, you should carefully read this prospectus and any related prospectus supplement.

We may offer and sell these securities to or through one or more underwriters, dealers and agents,